adenovirus-mediated crispr/cas9 gene editing in patient ......adenovirus-mediated crispr/cas9 gene...
Post on 26-Sep-2020
5 Views
Preview:
TRANSCRIPT
Adenovirus-mediated CRISPR/Cas9 gene editing in patient primary fibroblasts to validate potential drug targets in lung fibrosisAnne-Marie Zuurmond1,#, Liesbeth Veugen1, Lieke Geerts1, Barbara Killian2, Isabella Gazzoli1, Dennis Gravekamp1, Monique Hazenoot1, Miranda van der Ham1, Britt Sotthewes1, Brigitta Witte1, Krista Ouwehand1, David Fischer3, Jeroen DeGroot1
1Charles River Leiden, Darwinweg 24, 2333 CR Leiden, The Netherlands; 2Charles River Wilmington, 251 Ballardvale St, Wilmington, MA 01887, USA; 3Charles River Cambridge, Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom#Corresponding author: Anne-Marie.Zuurmond@crl.com
1 INTRODUCTIONTargeted gene editing has become a key tool in deciphering the molecular mechanisms underlying disease processes and for target validation in the drug discovery process. For research into new drug targets and compounds for treatment of pulmonary fibrosis, we previously developed a cell-based assay with primary lung fibroblasts derived from idiopathic pulmonary fibrosis (IPF) patients. In this in vitro model, the transition of fibroblast into myofibroblast (FMT) is triggered by TGFβ. Myofibroblasts are thought to play a major role in fibrosis through excessive deposition of extracellular matrix. A key feature of myofibroblasts is the production of α-smooth muscle actin (αSMA).
Figure 1: Cell-based phenotypic assay for pulmonary fibrosis
In this study, we have evaluated the feasibility to validate potential drug targets in fibrosis by CRISPR/Cas9-mediated targeted gene knockout in this assay. For delivery of Cas9 and gRNA the adenoviral system was chosenthat is known for its ability to transduce a wide range of cells with high efficiency, including human primary lungfibroblasts that are difficult to transfect. The ACTA2 gene encoding αSMA was selected as target to demonstratefeasibility of CRISPR/Cas9-mediated knockout in lung fibroblasts. The setup was validated using a small gRNAlibrary with putative drug targets for FMT/IPF emerging from literature.
2 EXPERIMENTAL DESIGNAn adenoviral system for CRISPR/Cas9 delivery was constructed with Cas9 and the gRNA being expressed fromtwo different adenoviruses (AdV). Four gRNAs targeting ACTA2 and ≥2 gRNAs per putative drug target weredesigned and cloned into the adapter vector of the adenoviral system. High titer stocks of adenoviruses expressingeither Cas9 or ACTA2 gRNAs were produced and used in the transduction of primary fibroblasts derived from fourIPF patients. CRISPR/Cas9-mediated knockout of ACTA2 was measured by high content analysis (HCA).
Figure 2. Timeline for a cell-based phenotypic assay for lung fibrosis. Fibroblasts derived from IPF patientswere transduced with AdV-Cas9 and AdV-gRNA one day after seeding. The fibrotic process was triggered byadding 2 ng/µl TGFβ 4 days after adenoviral transduction. The fibroblast to myofibroblast transition (FMT)was quantified by measuring αSMA production by high content analysis (HCA) 2 days after adding theTGFβ trigger.
3 RESULTS
Figure 3. Impaired αSMA production in FMT assay due to CRISPR/Cas9-mediated ATCA2 knockout. IPF patient-derived fibroblasts from four donors (IPF03, -05, -07 and -08) were transduced at a MOI of 24 each for AdV-Cas9 and AdV-gRNA_ACTA2 (ACTA2 _g). TGFβ was added 4 days after transduction and αSMA production was quantified by HCA 2 days after TGFβ trigger (day 7). A non-targeting control adenovirus (AcGFP_g1) was used to normalize the data as adenoviral transduction is known to stimulate αSMA production. All four gRNAs were effective in ACTA2 gene knockout in two independent experiments, however gene editing efficiency was donor-dependent. Typical high content images are shown.
4 CONCLUSION
Table 1: Selection of putative drug targets for modulation of αSMA protein levelsin the FMT process. Candidate genes are selected that are presumed to beinvolved in IPF based on available literature. The ACTA2 gene is selected as anassay control. For each target gene ≥2 gRNAs were designed and cloned into theadapter vector of the adenoviral system.
We conclude that adenoviral transduction of primary fibroblasts for targeting gene editing using CRISPR/Cas9 technology is sufficiently efficient to assess the effects of a gene knockout in a cell-based assay such as the FMT assaywithout the need for selection or cloning. This was validated not only by targeting the ACTA2 gene encoding for αSMA protein directly, but also using a small library of gRNAs targeting genes that are associated with the fibrosis processand/or IPF phenotypes. Using this approach IRIF5, ITGA5, COL3A1 and SMAD4 are identified as modulators of myofibroblast transition in this assay. Such effective gene targeting in a functional assay is a valuable asset for targetvalidation in drug discovery.
CRISPR-Cas9 was used under license to granted and pending US and international patents from the Broad Institute and ERS Genomics Limited
TGFβ
Myofibroblast
DAPI aSMA
Fibroblast
Refresh medium
D7
Fix and stain cells
D1
AdV transduction
D2 D5
Add TGFβ
αSMA and DAPI immunostaining measured by HCA
Seed IPF cells
Unt
reat
ed (n
on-tr
igge
red)
Unt
reat
ed (t
rigge
red)
Cru
de ly
sate
(trig
gere
d)
AcG
FP_g
1 (tr
igge
red)
AC
TA2_
g1 (t
rigge
red)
AC
TA2_
g2 (t
rigge
red)
AC
TA2_
g3 (t
rigge
red)
AC
TA2_
g4 (t
rigge
red)
0.0
0.5
1.0
1.5
αSM
A / N
ucle
i(n
orm
aliz
ed to
AcG
FP_g
1)
IPF08 (Exp A)IPF03 (Exp B)IPF05 (Exp B)
IPF07 (Exp A) non-triggered
triggered
crude lysate
AcGFP_g1
ACTA2_g1
ACTA2_g2
ACTA2_g3
ACTA2_g4
controls gRNA
Gene Full name Rationale
ACTA2 Actin alpha 2, smooth muscle Involved in vascular contractility, is used as a FMT marker
IRF5 Interferon regulatory factor 5 Transcription factor modulating cell growth and differentiation
ITGA5 Integrin subunit alpha 5Involved in the formation of the fibronectin receptor, cell surface adhesion
and signaling
ITGB7 Integrin subunit beta 7Adhesion receptor involved in cellular signaling with the extracellular matrix
and MAPK-ERK pathway
ITGB1 Integrin subunit beta 1Involved in the formation of the fibronectin receptor and tissue repair
processes
COL3A1 Collagen type III alpha 1 chainFibrillary collagen found in extensible connective tissue, is used as a FMT
marker
TGFBR3Transforming growth factor beta
receptor 3Membrane proteoglycan often functioning as a co-receptor with other TGFβ
receptor superfamily members
SMAD4 SMAD family member 4Signal transduction protein involved in TGFβ signaling regulating
transcription processes
MAPK8 Mitogen-activated protein kinase 8Regulation of kinases signaling processes involved with cell proliferation and
differentiation associated with renal fibrosis and fatty liver disease
CXCL10 C-X-C motif chemokine ligand 10Ligand for the receptor CXCR3 and inflammation marker, involved with
adhesion molecule expression
S100A8 S100 calcium binding protein A8Involved in the regulation cell cycle progression and differentiation
associated with cystic fibrosis 0.0
0.5
1.0
1.5
ITGB7_g4ITGB7_g1
MAPK8_g3MAPK8_g2MAPK8_g4
CXCL10_g3CXCL10_g1CXCL10_g2CXCL10_g4
ITGB1_g1ITGB1_g2ITGB1_g3ITGB1_g4
TGFBR3_g3TGFBR3_g2TGFBR3_g4TGFBR3_g1S100A8_g4S100A8_g2S100A8_g1S100A8_g3ITGA5_g4 ITGA5_g2ITGA5_g3
IRF5_g2IRF5_g1 IRF5_g4IRF5_g3
SMAD4_g1SMAD4_g2SMAD4_g3SMAD4_g4
COL3A1_g1COL3A1_g2COL3A1_g3
ACTA2_g4ACTA2_g3ACTA2_g2ACTA2_g1AcGFP_g1
Crude lysateUntreated (triggered)
Untreated (non-triggered)
IPF03 (Exp B)
αSM
A /
Nuc
lei
(nor
mal
ized
to A
cGFP
_g1)
0.0
0.5
1.0
1.5
IPF05 (Exp B)
0.0
0.5
1.0
1.5
IPF07 (Exp C)
0.0
0.5
1.0
1.5
IPF08 (Exp C)
Controls
SMAD4
IRF5
ITGA5
S100A8
TGFBR3
ITGB1
CXCL10
MAPK8
ITGB7
COL3A1Not tested
Not tested
Not tested
Not tested
Not tested
Not tested
Not tested
Not tested
Not tested
Not tested
Not tested
Not tested
Not tested
Not tested
Not tested
Not tested
Not tested Not tested
100% 18% 72% 59% 50% 42% 48%
AcGFP_g1 ACTA2_g4 IRF5_g3 COL3A1_g2 COL3A1_g3 SMAD4_g4ITGA5_g3
Figure 5. Representative high content images of CRISPR/Cas9-mediated ATCA2, IRIF5, ITGA5, COL3A1 and SMAD4 knockout using the top-performing gRNAs indonor IPF07. Relative percentage αSMA / nuclei levels from high content analysis is given normalized to the non-targeting control adenovirus (AcGFP_g1).
Figure 4: CRISPR/Cas9-mediated downregulation of αSMA protein in FMTassay was observed using gRNA directed against IRIF5, ITGA5, COL3A1 andSMAD4. The relative effect size for modulation of each of these targets wasdonor- and gRNA-dependent and varied between the two experiments.Percentage αSMA / nuclei levels is given normalized to the non-targetingcontrol adenovirus (AcGFP_g1). Non-triggered, TGFβ-triggered, crudelysate/TGFβ-treated and ACTA2 gRNA-exposed fibroblasts were taken along ascontrols. Dark green: ≤50%; light green: 51-75%; grey: ≥76%.
top related